108166-22-9

Basic information

• Product Name: 4-[(2-methylbenzoyl)amino]benzoic acid
• Synonyms: 4-[(2-methylbenzoyl)amino]benzoic acid;4-(2-MethylbenzaMido)benzoic acid
• CAS NO: 108166-22-9
• Molecular Formula: C₁₅H₁₃NO₃
• Molecular Weight: 255.26862
• Mol File: 108166-22-9.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 374.575 °C at 760 mmHg
• Flash Point: 180.337 °C
• Appearance: /
• Density: 1.29
• CAS DataBase Reference: 4-[(2-methylbenzoyl)amino]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(2-methylbenzoyl)amino]benzoic acid(108166-22-9)
• EPA Substance Registry System: 4-[(2-methylbenzoyl)amino]benzoic acid(108166-22-9)

Safety Data

• Hazardous Substances Data: 108166-22-9(Hazardous Substances Data)

Usage

General Description

4-[(2-Methylbenzoyl)amino]benzoic Acid is an organic compound typically known for its use in scientific research. It consists of both benzoyl and amino groups attached to a benzoic acid structure, making it a member of the phenylbenzamides and anilides family. The molecular formula for this compound is C15H13NO3, and it is often recognized by its systematic name - benzoic acid, 4-[(2-methylphenyl)amino]-. This synthetic compound does not occur naturally, and is usually available in the form of a white to off-white powder. It is typically stored and transported in a sealed and safe container to avoid any physical damages or enzymatic degradation.

Upstream product

• 94-09-7 p-aminoethylbenzoate 
• 118-90-1 ortho-methylbenzoic acid 
• 933-88-0 ortho-toluoyl chloride 
• 619-45-4 4-methoxycarbonyl aniline 
• 200278-95-1 methyl 4-(2-methylbenzamido)benzoate 

Downstream Products

• 1258550-51-4 2-methyl-N-(4-(3-nitro-4-(2-(phenylthio)ethylamino)phenylsulfonylcarbamoyl)phenyl)benzamide 
• 168078-78-2 N-[4-(7,8-Methylenedioxy-5H-imidazo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-methylbenzamide 
• 168078-85-1 N-[4-(4H-Furo[2,3-e]pyrrolo[1,2-a][1,4]diazepin-10-(9H)-ylcarbonyl)phenyl]-2-methylbenzamide 
• 911211-85-3 2-methyl-N-[4-(5H-pyrrolo[2,1-c][1,4]-benzodiazepin-10(11H)-ylcarbonyl)-phenyl]benzamide 
• 1296194-50-7 N-{4-[(5,9-dimethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-1-yl)carbonyl]phenyl}-2-methylbenzamide 
• 1296194-49-4 N-{4-[(9-chloro-5-methyl-4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-1-yl)carbonyl]phenyl}-2-methylbenzamide 
• 1296194-48-3 N-{4-[(5,9-dimethyl-4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-1-yl)carbonyl]phenyl}-2-methylbenzamide 
• 1283597-05-6 2-methyl-N-(4-(5,6,7,12-tetrahydrodibenzo[b,g][1,5]diazocine-6-carbonyl)phenyl)benzamide 

Relevant articles and documents

Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity

On the basis of the comparison of the structure of the Bim BH3: Bcl-x L complex and that of the ABT-737: Bcl-xL complex, a series of class A compounds were designed. These compounds had the basic skeleton of ABT-737 and the h2 residues of Bim BH3. These residues had shown themselves to be relevant to Bim BH3's broad-spectrum binding properties in saturation mutagenesis assays. Unlike ABT-737, which is a selective inhibitor of anti-apoptotic members of the Bcl-2 protein family, the class A compounds showed broad-spectrum binding activity to target proteins similar to those of Bim BH3 peptide. Then class B compounds were synthesized by modifying the structure of the most effective class A compound, A-4. Most of these class B compounds showed better binding affinity to the target proteins than the class A compounds had. They also showed themselves more effective than ABT-737 at inhibiting growth in multiple tumor cell lines known to express Bcl-x L, Bcl-2, and Mcl-1 proteins at high levels. Compounds B-11 and B-12 had the strongest anti-tumor activity of any compounds we produced. This study suggests that it is feasible to design small-molecule inhibitors based on the structure of Bim BH3, which shows broad-spectrum binding to Bcl-xL, Bcl-2, and Mcl-1 proteins. Our results also suggest that the broad-spectrum properties of small-molecule inhibitors binding to target proteins play a critical role in inhibiting the growth of many tumor cells. Finally, our study provides a series of lead compounds that merit further research into anti-cancer therapeutics.

Structure-activity study of novel tricyclic benzazepine arginine vasopressin antagonists

Novel tricyclic benzazepine derivatives were synthesized as arginine vasopressin (AVP) antagonists. Several tricyclic compounds showed potent antagonistic activity in rat AVP receptors V1a and V2. Derivatives containing pyrrolo-tricy

TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS

-